Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to our new Arthritis Research UK Clinical Research Fellows, Dr Malvika Gulati and Miss Jennifer Lane on their successful Fellowship applications.

Jennifer will be studying the “Epidemiology of common hand conditions”. The project will study trends in disease variation and the surgical management of the condition at a national level using routinely collected UK GP and hospital data. Two large research studies, UK Biobank and the Million Women Study, will also be used to study over 1.8 million people to consider risk factors in developing severe osteoarthritis.

Commenting on the news of her successful application Jennifer stated “I'm thrilled to be working with ARUK for this project that I hope will help us better understand why people develop hand conditions, and aid us in determining the best surgical treatments for the future."

Jennifer will be sponsored by Prof Dominic Furniss, Prof Daniel Prieto-Alhambra and Prof Jane Green at the Million Women Study based in the Cancer Epidemiology Unit at the Nuffield Department of Population Health.

Dr Malvika Gulati will be looking at ”The role of gender, menopause and sex hormones in painful hand osteoarthritis (OA)”. Hand OA is common, affecting 2 million people in the UK and can cause pain, swelling and deformity and has greater occurrences in women. The project aims to improve understanding of the role of gender and hormonal influences in the pathogenesis of painful hand OA, in order to predict individual outcomes and identify new treatment strategies.

On acceptance of the award Malvika stated "I am grateful for the opportunity that Arthritis Research UK has given us. Hand osteoarthritis is the most common form of arthritis in the hand, yet treatment options are limited. This funding will allow us to better understand the condition and test our hypothesis that hormones may play a role in its development.”  

Malvika will be sponsored by Prof Fiona Watt, Prof Tonia Vincent and Prof Nigel Arden.

Funding Body

ARUK logo

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).